Tolvaptan in ADPKD Patients With Very Low Kidney Function

Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference

(2020) Andrew S. Levey et al.   KIDNEY INTERNATIONAL

Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

(2020) Vicente E. Torres et al.   Clinical Journal of the American Society of Nephrology

Autosomal dominant polycystic kidney disease

(2019) Emilie Cornec-Le Gall et al.   LANCET

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

(2017) Vicente E. Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

(2016) Ron T. Gansevoort et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function

(2015) Wendy E. Boertien et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

(2012) Vicente E. Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease

(2011) Maria V. Irazabal et al.   KIDNEY INTERNATIONAL

Autosomal Dominant Polycystic Kidney Disease

(2008) Jared J. Grantham   NEW ENGLAND JOURNAL OF MEDICINE